Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Alternext  >  Theranexus    ALTHX   FR0013286259

THERANEXUS

(ALTHX)
  Report  
Delayed Quote. Delayed Euronext Alternext - 12/05 11:21:08 am
2.43 EUR   +0.41%
10/15THERANEXUS : Theranexus reports cash position as of september 30, 2019
AN
10/15THERANEXUS : 3rd quarter earnings
CO
09/26THERANEXUS : Theranexus announces its first half 2019 results
AN
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Alternext
11/29/2019 12/02/2019 12/03/2019 12/04/2019 12/05/2019 Date
2.41(c) 2.43(c) 2.45(c) 2.42(c) 2.43(c) Last
16 003 2 887 4 482 11 656 8 246 Volume
+2.55% +0.83% +0.82% -1.22% +0.41% Change
More quotes
Financials (EUR)
Sales 2019 0,07 M
EBIT 2019 -6,60 M
Net income 2019 -5,80 M
Finance 2019 5,10 M
Yield 2019 -
Sales 2020 22,1 M
EBIT 2020 7,10 M
Net income 2020 12,0 M
Finance 2020 4,85 M
Yield 2020 -
P/E ratio 2019 -1,75x
P/E ratio 2020 0,24x
EV / Sales2019 55,5x
EV / Sales2020 0,18x
Capitalization 8,80 M
More Financials
Company
Theranexus specializes in the research and development of therapeutic products for the treatment of diseases affecting the central nervous system. At the end of 2017, the group had one product in Phase II clinical development (THN102; treatment of narcolepsy-related sleep-wake disorders and... 
More about the company
Surperformance© ratings of Theranexus
Trading Rating : - Investor Rating :
More Ratings
Latest news on THERANEXUS
10/15THERANEXUS : Theranexus reports cash position as of september 30, 2019
AN
10/15THERANEXUS : 3rd quarter earnings
CO
09/26THERANEXUS : Theranexus announces its first half 2019 results
AN
09/24THERANEXUS : A new milestone reached for theranexus: inclusion of last patient i..
AN
09/17THERANEXUS : Theranexus announces inclusion of last subject in its phase ib tria..
AN
09/03THERANEXUS : Theranexus announces the publication of two scientific papers and a..
AN
07/11THERANEXUS : Theranexus raises approximately 2.2 million euros in a placement re..
AN
07/10THERANEXUS : Theranexus announces the launch of a capital increase by private pl..
AN
07/10THERANEXUS : Admission of new securities
CO
07/08THERANEXUS : Theranexus reports cash position as of june 30, 2019
AN
06/27THERANEXUS : Theranexus and Beyond Batten Disease Foundation (BBDF) announce agr..
AN
06/20THERANEXUS : THERANEXUS INVITED TO JOIN IN THE HEALTHTECH INVESTOR DAYS (HTID) 2..
AN
06/04THERANEXUS : Theranexus announces the formation of its scientific board
AN
05/23THERANEXUS : Theranexus to present new data on neuron-glia interactions at two s..
AN
04/24THERANEXUS : Theranexus announces issuance of chinese patent covering its drug c..
AN
More news
News in other languages on THERANEXUS
10/16EN DIRECT DES MARCHES : Ipsen, Soitec, DBV Technologies, FDJ, Roche, Google, ..
10/16STOCK MARKET PARIS : Le verre à moitié plein
10/16BIOTECH TIME : Ipsen tente le pari BLU-782, DBV boucle sa levée de fonds, Nicox ..
10/15THERANEXUS : Theranexus publie sa position de trésorerie au 30 septembre 2019
09/27EN DIRECT DES MARCHES : ArcelorMittal, Airbus, Carrefour, Altran, Inventiva, ..
More news
Sector news : Bio Therapeutic Drugs
09:26aREGENERON PHARMACEUTICALS : Reports Positive Phase 2 Data for Pozelimab in PNH
DJ
12/04Glencore to Change 'Old Guard' Ahead Of CEO Transition -- WSJ
DJ
11/28Novartis's $90 million Swiss factory to help solve cell therapy bottleneck
RE
11/28China's major shareholders sell A-shares, pressuring markets
RE
11/27REGENERON PHARMACEUTICALS : Early Drug Treatment Sharply Reduces Deaths From Ebo..
DJ
More sector news : Bio Therapeutic Drugs
Chart THERANEXUS
Duration : Period :
Theranexus Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends THERANEXUS
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 3
Average target price 10,27  €
Last Close Price 2,43  €
Spread / Highest target 435%
Spread / Average Target 322%
Spread / Lowest Target 188%
EPS Revisions
Managers
NameTitle
Franck Joseph Louis Mouthon Chairman & Chief Executive Officer
Thierry Bertrand Lambert Chief Financial Officer
Mathieu Bernard Mari Charveriat Deputy CEO, Director & Chief Scientific Officer
Werner Rein Chief Medical Officer
Dominique Costantini Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
THERANEXUS-86.44%10
GILEAD SCIENCES6.71%84 448
VERTEX PHARMACEUTICALS35.12%57 578
REGENERON PHARMACEUTICALS-0.95%40 446
WUXI APPTEC CO., LTD.68.15%20 724
GENMAB49.32%15 646